NASDAQ · AVTE
Healthcare · Biotechnology
$2.68
Up+$0.00 (+0.00%)
Updated Sep 10, 2026, 11:51 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
AVTE does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning AVTE.
AVTE research
Company profile and research snapshot.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 18, 2024 | Guggenheim | Neutral | — |
| Jun 18, 2024 | Evercore ISI Group | In-Line | — |
| Jun 18, 2024 | Wells Fargo | Equal-Weight | — |
| Jun 18, 2024 | TD Cowen | Hold | — |
| Jun 17, 2024 | BTIG | Neutral | — |
No generated briefing is available yet.
defenseworld.net · Nov 29, 2025
Aerovate Therapeutics, Inc. (NASDAQ: AVTE - Get Free Report) dropped 0.5% during mid-day trading on Friday. The company traded as low as $12.30 and last traded at $12.48. Approximately 136,019 shares were traded during mid-day trading, an increase of 994% from the average daily volume of 12,438 shares. The stock had previously closed at $12.54.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AVTE.
No results
No recent SID articles mention AVTE.
